An example of a Suitable protein is the enzyme collage nase which comprises at least two covalently linked enzyme domains, one which binds collagen and another which has proteolytic capabilities and cuts the collagen Strand. This catalytic proteolytic domain, whether part of the full-length enzyme, i.e. the naturally occurring active enzyme, or just a proteolytic domain prepared by recombination, has the ability to cleave marker substrates of different types.
Examples of Suitable marker Substrates for collagenase are peptides provided with fluorescent markers or UV mark erS. Examples of marker Substrates for enzymes of this kind Examples of a "protein which contains at least one binding domain and at least one catalytic domain" are the members of the matrixins, the enzymes gelatinase, collagenase-1, neutrophil collagenase or matrix metallopro teinase of type 13 (I. Massova et al., The FASEBJournal 12, 1075 -1095 (1998 ).
The detection of a test Substance is indicated in the method of the invention by the protein converting the marker Substrate at a higher conversion rate. In contrast to inhibitors according to the prior art, the Substances of the invention do not inhibit the catalytic domain but rather interfere with binding of the Substrate to the binding domain (S) of the enzyme. The Substances of the invention produce an inhibition with improved specificity, Since they do not attack the catalytic domain, which occurs in many enzyme types.
In one example of the method of the invention, the protein used is collagenase, the Substrate used is type II collagen and the marker Substrate used is (7-methoxycoumarin-4-yl) acetyl-Pro-Leu-Gly-Leu-(3-2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH. (SEQ ID NO: 1).
The invention further relates to a test kit for carrying out the method of the invention, which comprises the compo In addition to the compound 4-(diphenylmethylene)-1-4-(p-fluorophenyl)-4-phenyl-3-butenylpiperidine, owing to the pharmacological properties, protamine Sulfate and also oligosaccharides and tetrasaccharides, which are obtained from heparin degradation, are also Suitable for the prophy laxis and therapy of all those disorders whose course involves increased activity of matrix-degrading enzymes Such as collagenases, metalloproteinases or aggrecanase. This includes degenerative joint disorderS Such as Osteoarthroses, spondyloses, chondrolysis after joint trauma or prolonged immobilization of joints after meniscus or patella injuries or tearing of ligaments. This further includes also disorders of the connective tissue Such as collagenoses, periodontal disorders, wound-healing disturbances and chronic disorders of the locomotor apparatus Such as inflammatory, immunologically or metabolically caused acute and chronic arthritis, arthropathies, myalgias and The invention also relates to a method for preparing a pharmaceutical, which comprise S bringing 4-(diphenylmethylene)-1-4-(p-fluorophenyl)-4-phenyl-3-butenylpiperidine together with a pharmaceutically The pharmaceutical products are typically prepared and administered in dosage units, each unit containing as active constituent a particular dose of the compound of the invention, 4-(diphenylmethylene)-1-4-(p-fluorophenyl)-4-phenyl-3-butenylpiperidine. In the case of Solid dosage units Such as tablets, capsules, coated tablets or Suppositories, Said dose can be up to about 1000 mg, but is typically from about 50 to about 300 mg, and in the case of injection Solutions in ampoule form up to about 300 mg, but typically from about 10 to about 100 mg. For the treatment of an adult patient about 70 kg in weight, daily doses of about 20 mg to about 1000 mg, typically from about 100 mg to about 500 mg, of active ingredient are indicated. Under certain circumstances, however, higher or lower daily doses Vated according to the manufacturers instruction, and diluted to 10 ug/10 ml with TCB buffer. TCB buffer was prepared by dissolving 10 mM tris(hydroxymethyl) amino methane (Sigma-Aldrich Chemie GmbH, Deisenhofen, Germany) in water and adjusting the pH to 7.5 with HC1. 100 mM CaClx2H2O (Merck KGaA, Darmstadt, Germany) and 0.05% of Brij 35 solution, 30% (w/v) (Sigma Aldrich Chemie GmbH, Deisenhofen, Deutschland), are added to Said Solution.
COMPONENTB)
Marker Substrate Solution A solution of 10 mmol/l (7-methoxycoumarin-4-yl )acetyl-Pro-Leu-Gly-Leu-(3-2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH. (SEQID NO: 1). (Bachem Biochemica GmbH, Heidelberg, Germany) in dimethyl sul foxide (DMSO) (Riedel-de Haen AG, Seelze, Germany) was diluted 1:40 (v/v) with water.
COMPONENTC)
Collagen II Solution 10 mg of human collagen 11 (Biocon, Potsdam, Germany) were dissolved in 2400 ul of 10 mmol/l acetic acid (72 hours at 4 C.), and then 1300 ul of a sodium bicarbonate solution (250 mmol/l) CaClx2H2O (Merck KGaA, Darmstadt, Germany) were added dropwise. COMPONENT D)
Test Substance (Suspected inhibitor or ligand), typically dissolved in water at an appropriate concentration relative to the amount of enzyme used.
Test Protocol
The components A) (25ul), B) (5ul), C) (10 ul) and D) (10 ul) were mixed in a total volume of 50 ul, and fluores cence was measured in a commercial spectrofluorimeter after 15 minutes (excitation at 330 nm, emission at 390 nm, Spectrafluor plus, Tecan Deutschland GmbH, Crailsheim, Germany).
Enzyme and inhibitor were preincubated at room tem perature for 15 min. The reaction was Started by adding 5 ul of marker substrate solution (component B at 25uM).
The fluorescence in example 1 was set at 100%, and the measured values of the other examples are based on this value. Table 1 shows the results. Examples 3, 5 and 6 illustrate the method of the invention, which makes it possible to detect novel inhibitors or ligands. These are distiguished by producing fluorescence values of 50-99% at a concentration of up to 500 umol/l, typically 50 tumol/l or less, in particular also Starting from 1 nmol/l, and in exceptional cases down to 0.1 nmol/l. 
